Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dotinurad-HF: Effect of dotinurad on eGFR decline in chronic heart failure with hyperuricemia
jRCTs041250020Recruiting
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dotinurad in chronic heart failure (CHF), hyperuricemia and chronic kidney disease (CKD). Primary endpoint: Change in eGFR slope. Started May 2025; status: recruiting.
02
Drugs
dotinurad
03
Conditions
chronic heart failure (CHF)hyperuricemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCTs041250020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250020.